This was the stock's second consecutive day of gains.

As the U.S. stock market navigates a period of heightened volatility, with major indexes experiencing significant fluctuations amid tariff discussions and economic uncertainties, investors are keenly ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, ...

Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products.

Read Our Latest Report on VRTX Vertex Pharmaceuticals Stock Up 1.8 % VRTX opened at $484.22 on Friday. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88. The ...

On CNBC's “Halftime Report Final Trades ,” Joshua Brown of Ritholtz Wealth Management picked CrowdStrike Holdings, Inc. CRWD.

The last upgrade for Vertex Pharmaceuticals Inc happened on February 12, 2025 when Canaccord Genuity raised their price target to $424. Canaccord Genuity previously had a sell for Vertex ...

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (VRTX) (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada ...

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.